Braveheart Bio shows large-scale bullish insider buying and a balance sheet that screens maximally conservative on leverage, but broader quality concerns persist with margin components at the bottom of their scale, and the peer ranking sits at the exact midpoint in every dimension. No current share price is available this run, so no trade setup or risk/reward can be computed.
Thesis pillars
- Flagged Quality Concerns→Stable
- Large Scale Insider Buying→Stable
- Maximally Conservative Leverage↑Improving
- +1 more pillar — see the Why tab for full reasoning
Braveheart Bio, Inc. (BRVE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.64: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin... Read more
Sell if holding. Engine safety override at $26.64: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-14Recent Developments — Braveheart Bio, Inc.
Latest news
- NEWS Braveheart Bio Q2 EPS $(2.51) — benzinga Sep 8, 2026 negative
- NEWS This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga Sep 1, 2026 positive
- NEWS Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48 — benzinga Aug 31, 2026 positive
- NEWS TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating — benzinga Aug 31, 2026 positive
- NEWS Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48 — benzinga Aug 31, 2026 positive
Generated 2026-09-14T07:11:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.64: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $24.78. Score 5.7/10, moderate confidence.
Take-profit target: $38.46 (+44.4% upside). Prior stop was $24.78. Stop-loss: $24.78.
Quality below floor (2.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -397.9%), Negative free cash flow.
Braveheart Bio, Inc. trades at a P/E of N/A (forward -13.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does Braveheart Bio, Inc. do?Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with...
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.